<DOC>
	<DOCNO>NCT02336399</DOCNO>
	<brief_summary>Chronic hepatitis B ( CHB ) serious liver disease worldwide , lead cause cirrhosis hepatocellular carcinoma ( HCC ) .HBsAg loss/seroconversion consider ideal endpoint antiviral therapy HBeAg-positive -negative patient , ultimate treatment goal CHB . However , patient achieve HBsAg loss would reverse back HBsAg positive , even occur HBV reactive . study , viral HBsAg response patient achieve HBsAg loss interferon treatment observe two year complete IFN treatment .</brief_summary>
	<brief_title>Sustained HBsAg Viral Response Patients Achieved HBsAg Loss Interferon Treatment</brief_title>
	<detailed_description>The patient chronic hepatitis B achieve HBsAg loss interferon treatment enrol observe 96 week . Serum HBV DNA , HBsAg , anti-HBs , HBeAg , anti-HBe measure every 3 month observation period , liver function test perform every 3 month also . The liver ultrasonic examination would take every 3-6 month . The primary endpoint HBsAg reverse back positive . The secondary endpoint HBV DNA reaction .</detailed_description>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>patient chronic hepatitis B achieve HBsAg loss interferon treatment . Active consumption alcohol and/or drug Coinfection human immunodeficiency virus , hepatitis C virus , hepatitis D virus History autoimmune hepatitis Psychiatric disease Evidence neoplastic disease liver</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>HBsAg loss , interferon , HBV reaction</keyword>
</DOC>